Project Grant F32CA301602
Award Date
12/27/25
Completion Date
6/30/28
Dollars Obligated
$162K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
The National Cancer Institute (NCI) awarded a $149,804 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh. The award will fund research to investigate the impact of the LAG3 protein on CD8+ T cell motility and migration in the context of cancer immunotherapy. The project aims to elucidate the mechanism by which LAG3 restricts T cell motility and determine if reduced motility impacts T cell infiltration into the tumor microenvironment. The...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The National Cancer Institute (NCI) awarded a $510,431 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The Johns Hopkins University. The grant, effective July 1, 2025 through June 30, 2030, supports comprehensive research to investigate the fundamental biological mechanisms underlying tumor dormancy, metastatic recurrence, and therapeutic resistance in aging melanoma patients. The research aims to uncover how the aging immune microenvironment influences tumor cell...
The National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health, awarded a $101,340 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Michigan. The award will fund research to investigate the role of the MS4A14 protein in regulating macrophage activation and antigen presentation, with the goal of improving immunotherapy response in cancer patients. The research...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...